ArQule, Inc. announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non- central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the wild-type form of the KRAS gene. Source: General Cancer News Articles Provided by Cancer Compass